ORIC Pharmaceuticals Enozertinib Shows 35% Objective Response Rate And 100% Disease Control Rate In Human Epidermal Growth Factor Receptor 2 Exon 20 Non-Small Cell Lung Cancer Patients

Benzinga · 2d ago
  • Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases
  • Manageable safety profile with low discontinuation rate
  • Enrollment completed; no further development planned in this patient population
  • Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET